Company intelligence / Profile preview
Arpeggio Biosciences
Boulder, Colorado, USAarpeggiobio.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Preclinical data show promising activity such as regression of aggressive adenocarcinoma tumors via an NRF2 degrader in vivo; significant tumor growth inhibition with GPX4 inhibitors; prevention of renal injury in mice models; neuronal cell death prevention in microglia models
- Therapeutic areas
- NeurologyOncologyNephrology
- Modalities
- Small moleculesBiological productsChemical drugsTranscriptomic sequencing-based drug discovery platform
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Builders VC (lead Series A investor)[5]Khosla Ventures[5]TechU Ventures[5]FundersClub[5]Tencent[5]Formic Ventures[5]Tau Ventures[5]Milad Alucozai/BoxOne Ventures [5]Matthew De Silva/Longtail Capital [5]FORMA Therapeutics collaboration to explore translational utility of drug candidates [8]
Beyond the preview
Go deeper on Arpeggio Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Arpeggio Biosciences.